1-(4-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)piperazin-1-yl)ethan-1-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-(4-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)piperazin-1-yl)ethan-1-one
• 英文别名: 4-(4-acetylpiperazin-1-yl)-2-(2-difluoromethylbenzimidazol-1-yl)-6-morpholino-1,3,5-triazine；1-[4-[4-[2-(difluoromethyl)benzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]piperazin-1-yl]ethanone
• 化学式: C₂₁H₂₄F₂N₈O₂
• 分子量: 458.471
• InChiKey: CFTQLFMYQDWTPI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  33
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  92.5
• 氢给体数：
  0
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  1-乙酰哌嗪 、 4-(4-氯-6-(2-(二氟甲基)-1H-苯并[d]咪唑-1-基)-1,3,5-三嗪-2-基)吗啉 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 以90%的产率得到1-(4-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)piperazin-1-yl)ethan-1-one
  参考文献：
  名称：

  IMMUNOSUPPRESSIVE AGENT COMPRISING A HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT

  摘要：

  公开号：

  EP1864665B1

文献信息

• PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY
  申请人：Rewcastle Gordon William

  公开号：US20100249099A1

  公开（公告）日：2010-09-30

  Provided herein are pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides, e.g., compounds of Formulae IA, IB, and IC, and their pharmaceutical compositions, preparation, and use as agents or drugs for cancer therapy, either alone or in combination with radiation and/or other anticancer drugs.

  本文提供了嘧啶基和1,3,5-三嗪基苯并咪唑磺胺类化合物，例如，式IA、IB和IC的化合物，以及它们的药物组合物、制备方法，以及作为癌症治疗药物或药剂的用途，可以单独使用，也可以与放疗和/或其他抗癌药物联合使用。
• Structure-Guided Design and Initial Studies of a Bifunctional MEK/PI3K Inhibitor (ST-168)
  作者：Marcian E. Van Dort、Stefanie Galbán、Charles A. Nino、Hao Hong、April A. Apfelbaum、Gary D. Luker、Greg M. Thurber、Lydia Atangcho、Cagri G. Besirli、Brian D. Ross

  DOI：10.1021/acsmedchemlett.7b00111

  日期：2017.8.10

  displays improved MEK1 and PI3K isoform inhibition, is described. ST-168 demonstrated a 2.2-fold improvement in MEK1 inhibition and a 2.8-, 2.7-, 23-, and 2.5-fold improved inhibition toward the PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ isoforms, respectively, as compared to a previous lead compound (4; ST-162) in in vitro enzymatic inhibition assays. ST-168 demonstrated superior tumoricidal efficacy over ST-162

  描述了一种新的单一实体MEK / PI3K双功能抑制剂（7，ST-168）的基于结构的设计，该抑制剂显示出改善的MEK1和PI3K同工型抑制作用。与以前的先导化合物相比，ST-168分别显示出对PI3Kα，PI3Kβ，PI3Kδ和PI3Kγ同工型的MEK1抑制作用提高了2.2倍，对PI3Kα，PI3Kβ，PI3Kδ和PI3Kγ的抑制作用分别提高了2.8、2.7、23和2.5倍。 （4；ST-162）在体外酶抑制试验中。在A375黑色素瘤球状肿瘤模型中，ST-168表现出优于ST-162的杀癌效果。ST-168比ST-162更有效在A375黑色素瘤小鼠模型中进行的肿瘤治疗研究中口服给药时，具有促进肿瘤控制的作用，证实了其对体内MEK1 / PI3K联合抑制的生物利用度和功效。
• IMMUNOSUPPRESSIVE AGENT AND ANTI-TUMOR AGENT COMPRISING HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT
  申请人：Haruta Kazuhiko

  公开号：US20080113987A1

  公开（公告）日：2008-05-15

  A novel method for immunosuppressive in a mammal suffering from an immune disease, including administering to the mammal a therapeutically effective amount of a heterocyclic compound represented by the general formula (I) (wherein X or other variables are as defined in the specification) or a pharmaceutically acceptable salt thereof is disclosed. A novel heterocyclic compound represented by the general formula (II) (wherein X or other variables are as defined in the specification) or a pharmaceutically acceptable salt thereof is also disclosed.

  本发明涉及一种治疗免疫性疾病的哺乳动物的免疫抑制新方法，包括向哺乳动物施用一种由通式（I）表示的杂环化合物的治疗有效量或其药学上可接受的盐。其中X或其他变量的定义见说明书。本发明还涉及一种由通式（II）表示的新型杂环化合物或其药学上可接受的盐。
• Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient
  申请人：Zenyaku Kogyo Kabushikikaisha

  公开号：US07750001B2

  公开（公告）日：2010-07-06

  A novel method for immunosuppressive in a mammal suffering from an immune disease, including administering to the mammal a therapeutically effective amount of a heterocyclic compound represented by the general formula (I) (wherein X or other variables are as defined in the specification) or a pharmaceutically acceptable salt thereof is disclosed. A novel heterocyclic compound represented by the general formula (II) (wherein X or other variables are as defined in the specification) or a pharmaceutically acceptable salt thereof is also disclosed.

  本文披露了一种在患有免疫疾病的哺乳动物中实现免疫抑制的新方法，包括向哺乳动物施用一种由通式（I）表示的杂环化合物的治疗有效量（其中X或其他变量如规范中所定义），或其药物可接受的盐。此外，本文还披露了一种由通式（II）表示的新型杂环化合物（其中X或其他变量如规范中所定义），或其药物可接受的盐。
• Multifunctional inhibitors of MEK/PI3K and mTOR/MEK/PI3K biological pathways and therapeutic methods using the same
  申请人：THE REGENTS OF THE UNIVERSITY OF MICHIGAN

  公开号：US10919877B2

  公开（公告）日：2021-02-16

  Multifunctional inhibitors of mTOR, MEK, and PI3K and compositions containing the same are disclosed. Methods of using the multifunctional inhibitors in the treatment of diseases and conditions wherein inhibition of one or more of mTOR, MEK, and PI3K provides a benefit, like cancers, also are disclosed.

  本发明公开了mTOR、MEK和PI3K的多功能抑制剂以及含有这些抑制剂的组合物。还公开了使用多功能抑制剂治疗疾病和病症的方法，在这些疾病和病症中，抑制 mTOR、MEK 和 PI3K 中的一种或多种可带来益处，如癌症。